Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Breast Neoplasms 108Carcinoma, Non-Small-Cell Lung 97Multiple Myeloma 81Prostatic Neoplasms 74Colorectal Neoplasms 60Neoplasms 58Leukemia, Myeloid, Acute 56Lymphoma 48Squamous Cell Carcinoma of Head and Neck 43Melanoma 40Lung Neoplasms 40Ovarian Neoplasms 38Neoplasm Metastasis 37Pancreatic Neoplasms 36Lymphoma, Non-Hodgkin 36Carcinoma, Hepatocellular 34Lymphoma, Large B-Cell, Diffuse 33Head and Neck Neoplasms 32Sarcoma 31Carcinoma, Renal Cell 31Urinary Bladder Neoplasms 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 30Endometrial Neoplasms 29Leukemia, Lymphocytic, Chronic, B-Cell 28Hodgkin Disease 28Triple Negative Breast Neoplasms 27Myelodysplastic Syndromes 27Hematologic Neoplasms 26Recurrence 25Glioma 25

Interventions

enasidenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Sinonasal undifferentiated carcinoma × 30 days × Clear all
NCT06176989 2026-06-03

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
40 enrolled
CNSSarcoma

Sinonasal undifferentiated carcinoma, Chondrosarcoma, Esthesioneuroblastoma, Olfactory

Data powered by HemOnc (CC BY 4.0) Colophon âš¡